Vebreltinib Bozitinib Application Scope

Vebreltinib (Bozitinib) is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and other solid tumors with EGFR mutations, for example, glioblastoma (GBM)，particularly those resistant to first-line therapies such as tyrosine kinase inhibitors (TKIs).

It is a tyrosine kinase inhibitor (TKI) that targets and inhibits the EGFR and HER2 pathways, involved in the growth and spread of cancer cells, making it particularly useful in treating cancers with certain genetic mutations. Vebreltinib has shown promising results in targeted therapy, improving progression-free survival in patients with EGFR exon 20 insertion mutations.

Vebreltinib Bozitinib Characteristics

Ingredients:
- Active ingredient: Bozitinib (Vebreltinib)
- Excipients: Includes stabilizers and other excipients.
Properties:Bozitinib is a TKI that specifically inhibits mutated EGFR and HER2 receptors. By targeting these mutations, it helps stop the growth of tumor cells, especially in NSCLC patients whose tumors have developed resistance to standard treatments.
Specification:Available in oral tablet form, typically in 100 mg and 200 mg doses.
Storage:Store at room temperature (20°C-25°C) in a dry place, away from light.
Expiry Date:The shelf life is generally 24-36 months depending on the specific batch. Check packaging for the exact expiry date.
Executive Standard:Meets international regulatory standards, such as FDA or EMA.
Approval Number:Approval details would vary by regulatory body.

Guidelines For The Use Of Vebreltinib Bozitinib

Dosage and Administration:

The recommended dose of Vebreltinib is usually 400 mg taken orally once daily, with or without food.
Treatment duration and dosage adjustments depend on the patient’s response and tolerability.

Adverse Reactions:

Common side effects include diarrhea, rash, fatigue, and nausea.
Serious side effects may include liver toxicity, pulmonary toxicity, and QT prolongation.

Medication Limitations

Contraindications:

Hypersensitivity to Bozitinib or any of the formulation components.
Contraindicated in patients with severe hepatic impairment.

Precautions:

Use with caution in patients with cardiovascular conditions, especially those with QT prolongation.
Liver function should be monitored regularly during treatment.

Vebreltinib Bozitinib Interactions

Drug Interactions:

Bozitinib may interact with CYP3A inhibitors or inducers and P-glycoprotein substrates, potentially affecting its efficacy and safety.
Antacids and H2 antagonists may alter absorption, so the timing of doses should be managed appropriately.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine, China Medicine Wholesaler.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.